With H1 2025 now in the rearview mirror, the biopharmaceutical industry is still grappling with a complex interplay of factors that are reshaping its growth trajectory. We investigate a recent report from GlobalData that highlights several critical trends that industry professionals are closely monitoring.
Evolving drug pricing policies and geopolitical tensions
The optimism surrounding pharmaceutical industry growth has notably waned, with many professionals attributing this shift to the new US administration’s policy changes. The introduction of the Most Favored Nation (MFN) executive order, which aims to reform drug pricing, has raised concerns about profitability and innovation within the sector. Coupled with the ever-changing potential for tariffs – both general and pharma-specific – these developments have created an atmosphere of uncertainty, particularly in the context of strained US-China relations.
Industry stakeholders are increasingly wary of how these geopolitical tensions could disrupt supply chains, impact investments and complicate pricing strategies. As tariffs continue to be an uncertainty even if they have been agreed already, the industry is bracing for further potential disruptions that could hinder the manufacturing and distribution of essential medications.
The rise of anti-obesity medications
Amid these challenges, one bright spot in the biopharmaceutical landscape is the surging demand for anti-obesity medications, particularly GLP-1 receptor agonists. These drugs are not only addressing a significant public health crisis but are also expanding into new therapeutic indications, presenting lucrative market opportunities. The increasing prevalence of obesity and its associated chronic diseases has made these medications a focal point for both clinicians and patients, particularly in North America and the Asia-Pacific region.
Advancements in antibody-drug conjugates and precision medicine
The interest in antibody-drug conjugates (ADCs) continues to gain momentum, with numerous partnerships and investments aimed at their development and manufacturing. This trend is closely tied to the broader movement towards personalised and precision medicine, which seeks to tailor treatments to individual patient profiles. As the industry pivots towards more targeted therapies, ADCs represent a promising avenue for innovation, despite the inherent challenges in drug development and manufacturing complexities.
The integration of artificial intelligence
Artificial intelligence (AI) remains a transformative force within the pharmaceutical value chain. Industry professionals are increasingly recognising AI’s potential to enhance drug discovery, streamline manufacturing processes and improve overall business efficiency. The integration of AI is expected to alleviate some of the research and development challenges that have historically plagued the industry, ultimately accelerating drug development timelines.
The shift towards real-world evidence (RWE)
The growing emphasis on real-world evidence (RWE) trials, leveraging data from digital devices, is another noteworthy trend. Regulatory bodies, including the US FDA and EMA, are playing a pivotal role in promoting the use of RWE, which is becoming increasingly important for both industry and non-industry sponsors. This shift towards RWE is expected to enhance the understanding of drug efficacy and safety in real-world settings, further informing treatment decisions.
Supply chain challenges and market dynamics
As the industry navigates these trends, supply chain challenges have emerged as a primary concern. A significant proportion of industry professionals now believe that these challenges, alongside pricing and reimbursement issues, will have the most substantial impact on the sector in the second half of 2025. The recent political climate, characterised by potential tariffs and a push for reshoring manufacturing, has intensified focus on supply chain resilience.
This all leaves the biopharmaceutical industry facing a confluence of challenges and opportunities. As professionals adapt to the changing landscape, the emphasis on anti-obesity medications, ADCs, AI integration and RWE will likely shape the future of drug development and patient care according to GlobalData’s report. However, the overarching uncertainty stemming from geopolitical tensions, the ever-changing tariff landscape and regulatory changes will require strategic navigation to ensure sustained growth and innovation in the sector.
